Back

The antifibrotic effect of empagliflozin: Insights from the EMPIRE trial programme

31 August 2026 (13:15 - 13:35)
Organised by: Logo
Congress Presentation Part of: Cardiac remodelling, fibrosis, and heart failure Vascular Diseases: Fibrosis ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jesper Jensen

Herlev and Gentofte Hospital, Copenhagen (Denmark)

2 More presentations in this session

Presentation thumbnail
PARP1 mediates the PI3K/AKT signaling pathway through PARylation-dependent to alleviate the myocardial injury caused by Cediranib
Mr X. Ma (Lanzhou, CN)
Abstract Slides Video
Presentation thumbnail
Itaconate reduces mitochondrial respiratory threshold and improves both inotropy and lusitropy in human hypertrophic myocardium
Doctor Y. Ng (Sydney, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac remodelling, fibrosis, and heart failure

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials
26 August 2023
thumbnail
Congress Presentation
Empagliflozin promotes reverse remodeling via cardiometabolic reprogramming in established pressure-overload left ventricular hypertrophy
30 August 2026
thumbnail
Congress Presentation
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: 'As-treated' analysis of the Reduce-MFA DZHK 25-trial
29 August 2026
thumbnail
Congress Presentation
Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)
31 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources